20 Facts About Venlafaxine


Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin-norepinephrine reuptake inhibitor class.

FactSnippet No. 1,124,797

Venlafaxine was approved for medical use in the United States in 1993.

FactSnippet No. 1,124,798

Venlafaxine is used primarily for the treatment of depression, general anxiety disorder, social phobia, panic disorder, and vasomotor symptoms.

FactSnippet No. 1,124,799

Venlafaxine is an antidepressant agent that can safely be used in patients with stroke history.

FactSnippet No. 1,124,800

Venlafaxine has been used off label for the treatment of diabetic neuropathy and migraine prevention .

FactSnippet No. 1,124,801

Related searches

United States

Venlafaxine was similar in efficacy to the atypical antidepressant bupropion; however, the remission rate was lower for venlafaxine.

FactSnippet No. 1,124,802

Venlafaxine has been shown to have an optimal efficacity and tolerability towards the lower end of their licensed dose range.

FactSnippet No. 1,124,803

Venlafaxine is not recommended in patients hypersensitive to it, nor should it be taken by anyone who is allergic to the inactive ingredients, which include gelatin, cellulose, ethylcellulose, iron oxide, titanium dioxide and hypromellose.

FactSnippet No. 1,124,804

Venlafaxine might interact with tramadol or other opioids, trazodone, so caution is needed while mixing multiple serotonergic agents together.

FactSnippet No. 1,124,805

Venlafaxine has a higher rate of moderate to severe discontinuation symptoms relative to other antidepressants .

FactSnippet No. 1,124,806

Venlafaxine-induced serotonin syndrome has been reported when venlafaxine has been taken in isolation in overdose.

FactSnippet No. 1,124,807

Venlafaxine should be taken with caution when using St John's wort.

FactSnippet No. 1,124,808

Venlafaxine is neither recommended nor approved for the treatment of major depressive episodes in bipolar disorder, as it can induce mania or mixed episodes.

FactSnippet No. 1,124,809

Venlafaxine appears to be more likely than the SSRIs and bupropion to induce mania and mixed episodes in bipolar patients.

FactSnippet No. 1,124,810

Venlafaxine can be abused as recreational drug, with damages that can manifest within a month.

FactSnippet No. 1,124,811

Venlafaxine is usually categorized as a serotonin-norepinephrine reuptake inhibitor, but it has been referred to as a serotonin-norepinephrine-dopamine reuptake inhibitor .

FactSnippet No. 1,124,812

Venlafaxine indirectly affects opioid receptors as well as the alpha2-adrenergic receptor, and was shown to increase pain threshold in mice.

FactSnippet No. 1,124,813

Venlafaxine is a substrate of P-glycoprotein, which pumps it out of the brain.

FactSnippet No. 1,124,814

Venlafaxine is structurally and pharmacologically related to the atypical opioid analgesic tramadol, and more distantly to the newly released opioid tapentadol, but not to any of the conventional antidepressant drugs, including tricyclic antidepressants, SSRIs, MAOIs, or RIMAs.

FactSnippet No. 1,124,815

Venlafaxine extended release is chemically the same as normal venlafaxine.

FactSnippet No. 1,124,816